Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Conceptus(R) to Present at the Stephens Fall Investment Conference.


MOUNTAIN VIEW, Calif. -- Conceptus, Inc. (NASDAQ: CPTS) announced today that Mark Sieczkarek, president and chief executive officer, will present at the Stephens Fall Investment Conference on Tuesday, November 18, 2008, at 1:30 p.m. EST. The conference will be held at the New York Palace Hotel.

A live webcast of the presentation will be available by going to www.conceptus.com and clicking on the link to Live Webcasts. An archived replay will be available for a period of 30 days.

About Conceptus, Inc.

Conceptus, Inc. (NASDAQ: CPTS), is a leader in the design, development and marketing of innovative women's healthcare. The Mountain View, Calif.-based company manufactures and markets Essure permanent birth control. The Essure procedure is available in the United States, Europe, Australia, New Zealand, Canada, Mexico, Central and South America and the Middle East.

Please visit www.essure.com for more information on the Essure procedure. Patients may call the Essure Information Center at 1-877-ESSURE-1 with questions or to find a physician in their area. Information about Conceptus is available at www.conceptus.com.

About the Essure([R]) Procedure

The Essure([R]) procedure is a permanent birth control method that can be done in the comfort of a physician's office about 13 minutes without hormones, cutting, burning or the risks associated with general anesthesia or tubal ligation. Small, flexible micro-inserts are placed in the woman's fallopian tubes through the cervix without incisions. Over the next three months, the body forms a natural barrier around the micro-inserts to prevent sperm from reaching the egg. Essure is 99.8 percent effective with zero pregnancies reported in clinical trials.

Three months after the Essure procedure, a doctor can perform an Essure Confirmation Test to confirm that the fallopian tubes are fully blocked and that the patient can rely on Essure for permanent birth control with full confidence. Essure was FDA-approved in 2002 and more than 180,000 women worldwide have undergone the Essure procedure.

Essure and Conceptus([R]) are registered trademarks of Conceptus Inc.

[c]2008. All rights reserved. Conceptus and Essure are registered trademarks and your Family is Complete your Choice is Clear is a service mark of Conceptus Inc.

COPYRIGHT 2008 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Conference news
Date:Nov 4, 2008
Words:362
Previous Article:RAM Energy Resources Reports Third Quarter 2008 Results.
Next Article:D&B Declares Quarterly Dividend.
Topics:

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles